A multi-centre, randomised, double-blind, placebo-controlled clinical trial of methylphenidate in the initial treatment of acute mania (MEMAP study)
European Neuropsychopharmacology Nov 30, 2017
Hegerl U, et al. - The antimanic efficacy and safety of methylphenidate in the initial treatment of acute mania were evaluated in this multi-center, randomized, double-blind, placebo-controlled clinical trial. The authors revealed that in the full analysis set, methylphenidate was well tolerated and safe. However, it failed to show efficacy in the treatment of acute mania.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
